Please type a plus sign (+) inside this box>	Ŧ	
--	---	--

		Complete if Known
Substitute for form 1449A/B/PTO	Application Number	10/802,280
INFORMATION DISCLOSURE	Filing Date	March 17, 2004
	First Named Inventor	Urata et al.
STATEMENT BY APPLICANT	Group Art Unit	1614
(Use as many sheets as necessary)	Examiner Name	R. J. Henley III
(Use as many sneets as necessary)	Attorney Docket Number	227832
Sheet 1 of 1		

		U.	S. PATENT DOCUMENTS			
	U.S. Patent Do				Γ	
Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate	
	<u> </u>	<b></b>				
		<del>-</del>			·	
		1			* - · · · · · · · · · · · · · · · · · ·	
		+				
	····		$\sim$			
		<del>                                     </del>				
		<del>                                     </del>				
<del></del>	<del>/</del>	<del> </del>				
	/	<del> </del>				
		<del> </del>				
-4		<del>                                     </del>				
$\leftarrow$		<del>                                     </del>				
		<del>                                     </del>			$\overline{}$	
		Doc. No. Application or Patent Number	U.S. Patent Document	Doc. Application or Patent Number Kind Code Name of Patentee or Applicant	Doc. Application or Patent Number Kind Code Name of Patentee or Applicant Date of Publication	

				FORE	IGN PATENT DOCUMENTS			
		F	oreign Patent Docume	nt			Translation	
Examiner Ipitines	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No++
/ <del>//-</del>	FS	EP	0 533 281	A1	Glaxo Group Limited	Mar. 24, 1993		<u> </u>
V								
				-				
				<u> </u>				
								l

		OTHER - NON PATENT LITERATURE DOCUMENTS		
Examiner Doc.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item			
Initials	Initials No. (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher city and/or country where published.		Yes	No**

Examiner Signature

Date Considered

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).